FindMyKOL
Clinical trialNCT03226431CompletedPhase 1Interventional

Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0

NCT03226431 is a phase 1 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Ascorbic acid in Lung Transplant. The registry lists an enrollment of 6 participants at 1 site in 1 country. The registry lists a start date of 11 Dec 2017 and a primary completion date of 25 Jun 2019.

SponsorDuke University →Enrollment6Lung Transplant
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03226431
FieldValue
Registry IDNCT03226431
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorDuke University
Enrollment6
Registered sites1
Countries1
ConditionsLung Transplant
DrugsAscorbic acid
Start11 Dec 2017
Primary completion25 Jun 2019
Study completion25 Jun 2019
Last update posted5 Jul 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

North Carolina, United States1 site
  • Duke University Medical Center

    Durham

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ascorbic acid
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03226431

Each answer restates registry values shown on this page.

What is NCT03226431?

NCT03226431 is a phase 1 interventional trial sponsored by Duke University. It studies Ascorbic acid in Lung Transplant.

Who leads NCT03226431?

The registry names Lorenzo Zaffiri, MD (principal investigator, Duke Health) and Omar Mohamedaly, MD (principal investigator, Duke Health) as overall officials.

Where does NCT03226431 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03226431 study?

The registered drug and biological interventions are Ascorbic acid.

When did NCT03226431 end?

The registry lists a primary completion date of 25 Jun 2019 and a study completion date of 25 Jun 2019. The sponsor last updated the record on 5 Jul 2019.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.